CRDF News and Press, Cardiff Oncology Inc. From 09/12/22

Clinical-stage biotech Cardiff Oncology ( NASDAQ: CRDF ) added ~14% in the pre-market trading Monday after the company announced Phase 1b/2 data for its lead asset Onvansertib in patients with KRAS-mutated metastatic colorectal cancer in a second-line setup. The data fea...

Cardiff Oncology Announces New Preclinical and Clinical Data from Program in KRAS-mutated Metastatic Colorectal Cancer (mCRC) at the ESMO Congress 2022 PR Newswire Durable responses to treatment, with a median duration of response (mDoR) of 11.7 months, reported in Pha...

Cardiff Oncology Announces Upcoming Poster Presentations at the ESMO Congress 2022 PR Newswire SAN DIEGO , Sept. 6, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop no...

Cardiff Oncology to Host Webcast and Conference Call to Provide a Clinical and Corporate Update on September 12, 2022 PR Newswire Event to feature discussions on the planned development pathway for onvansertib in KRAS-mutated metastatic colorectal cancer and updates on...

Today, we circle back on small developmental concern Cardiff Oncology for the first time since the fourth quarter of 2021. The company's primary drug candidate is targeting several indications in combination therapy with large potential markets. Numerous potential milestones lie o...

Cardiff Oncology press release ( NASDAQ: CRDF ): Q2 GAAP EPS of -$0.24 beats by $0.01 . Revenue of $0.09M (+28.6% Y/Y) beats by $0.02M . As of June 30, 2022, Cardiff Oncology had approximately $122 million in cash, cash equivalents, and short-term investments...

Cardiff Oncology Reports Second Quarter 2022 Results and Provides Business Updates PR Newswire Initial preclinical data in ovarian cancer presented at AACR showed treatment with onvansertib plus olaparib leading to a statistically significant survival benefit compared ...

Cardiff Oncology to Present at the William Blair Biotech Focus Conference 2022 PR Newswire SAN DIEGO , July 5, 2022 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop no...

Gainers: Cogent Biosciences (COGT) +56%. IO Biotech (IOBT) +9%. Celularity (CELU) +6%. PolarityTE (PTE) +6%. Aridis Pharmaceuticals (ARDS) +5%. Losers: Fulcrum Therapeutics (FULC) -48%. Caribou Biosciences (CRBU) -33%. DBV Technologies (DBVT) -18%. Card...

You can’t argue that biotech stocks were hit hard during the 2022 stock market crash. But that doesn’t mean opportunity was utterly stifled. Depending on your outlook and investment style, volatility has become a considerable asset to some. You know what I’m talking abo...